Rogaratinib (BAY1163877) in Chinese Patients

Summary

This study is planned to determine the safety and tolerability of rogaratinib in Chinese patients with fibroblast growth factor receptor (FGFR)-positive refractory, locally advanced, or metastatic solid tumors and to characterize the pharmacokinetics of rogaratinib in Chinese patients.

Timeline

Start

2019-01-07

Primary completion

2019-04-30

Completion

2020-04-14

Drugs

Indications